Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-2325a in Netherton Syndrome
NCT05979831Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of DS-2325a in Netherton syndrome (NS), sponsored by Daiichi Sankyo Co., Ltd.. Started Sep 2023; status: terminated.
02
Drugs
DS-2325a
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NCT05979831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979831.